A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).

Trial Details

NCT ID
NCT07622186
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SKB571 for injection
  • Osimertinib
  • Furmonertinib
  • carboplatin
  • Cisplatin
  • Pembrolizumab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Xiamen, Fujian, China|24.47979,118.08187
  • Dongguan, Guangdong, China|23.01797,113.74866

Key Eligibility Criteria

  • Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
  • Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  • At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →